Filed by newsfilecorp.com BUYINS.NET Consults to Lexaria Corp to Surveil Short Sellers and Market Makers. Approximately 26 Million Total Shares Shorted Since August 2009 Short Squeeze Expected When Stock Is Above $0.192

BUYINS.NET Consults to Lexaria Corp to Surveil Short Sellers

KELOWNA, BC / ACCESSWIRE / January 15, 2016 / Lexaria

Corp. (LXRP) (CNSX:LXX) (the "Company" or "Lexaria") announced today that

BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO

compliance monitoring, short sale trading statistics and market integrity

surveillance, has initiated coverage on Lexaria Corp. (OTC: LXRP) after

releasing the latest short sale data through January 14, 2016.

The total aggregate number of shares shorted since August 2009

is approximately 26 million shares. Approximately 40.82% of daily trading volume

is short selling. The SqueezeTrigger price for all LXRP shares shorted is

$0.192. A short squeeze is expected when the stock closes above the $0.192

SqueezeTrigger price.

Click here to view Report:

Click here for SqueezeTrigger:

Click here for Friction Factor:

http://www.buyins.com/images2/lxrpff1-14-16.jpg Friction Factor

calculates if a fair market is being made in the shares of LXRP.42% of the

previous 38 trading days have been positive or bullish-biased and 58% have been

negative or bearish-biased.

Regulation SHO requires bona-fide market-making activities to

include making purchases and sales in roughly comparable amounts. The Securities

and Exchange Commission has stated that bona-fide market-making DOES NOT include

activity that is related to speculative selling strategies for investment

purposes of the broker-dealer and is disproportionate to the usual market making

patterns or practices of the broker-dealer in that security. Likewise, where a

market-maker posts continually at or near the best offer, but does not also post

at or near the best bid, the market-maker's activities would not generally

qualify as bona-fide market-making. Moreover, a market-maker that continually

executes short sales away from its posted quotes would generally not be

considered to be engaging in bona-fide market-making.

BUYINS.NET will monitor LXRP market-makers daily for compliance

with Fair Market-Making Requirements, for an initial 6-month surveillance

period. Lexaria will always take all appropriate steps to encourage and ensure a

fair and transparent flow of information for its stakeholders.

Lexaria is a food sciences company focused on the delivery of

active compounds that can behave as superfoods through its proprietary infusion

technologies. Lexaria s technology enables higher bioavailability rates for CBD;

THC; NSAIDs; Nicotine and other molecules than is possible without lipophilic

enhancement technology. The Company uses innovative technology to deliver unique

food experiences. www.lexarienergy.com

BUYINS.NET, http://www.buyins.net, monitors trading in

all US stocks in real time and maintains massive databases of short sale and

naked short sale time and sales data, short squeeze SqueezeTrigger prices,

market-maker price movements, shareholder data, statistical data on earnings,

sector correlation, seasonality, hedge fund trading strategies and comparable

FOR FURTHER INFORMATION PLEASE CONTACT:

BUYINS.NET is not a registered investment adviser and nothing

contained in any materials should be construed as a recommendation to buy or

sell any securities. An affiliate of Lexaria Corp. has paid $1,167 per month for

six months of data provided in this and ongoing reports. LXRP believes the

information and data provided by buyins.net is accurate but has not verified it

and cautions all interested parties to verify data prior to making any

decisions. Please read our report and visit http://www.buyins.net, for complete

risks and disclosures.

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements

which are not historical facts are forward-looking statements. The Company makes

forward-looking public statements concerning its expected future financial

position, results of operations, cash flows, financing plans, business strategy,

products and services, competitive positions, growth opportunities, plans and

objectives of management for future operations, including statements that

include words such as "anticipate," "if," "believe," "plan," "estimate,"

"expect," "intend," "may," "could," "should," "will," and other similar

expressions are forward-looking statements, including but not limited to: the

provision of any significant investor relations or media relations services.

Such forward-looking statements are estimates reflecting the Company's best

judgment based upon current information and involve a number of risks and

uncertainties, and there can be no assurance that other factors will not affect

the accuracy of such forward-looking statements. Access to capital, or lack

thereof, is a major risk and there is no assurance that the Company will be able

to raise required working capital. Factors which could cause actual results to

differ materially from those estimated by the Company include, but are not

limited to, government regulation, managing and maintaining growth, the effect

of adverse publicity, litigation, competition, the patent application and

approval process and other factors which may be identified from time to time in

the Company's public announcements and filings. There is no assurance that

existing capital is sufficient for the Company's needs or that it will not need

to attempt to raise additional capital. There is no assurance that any planned

corporate activity, business venture, or initiative will be pursued, or if

pursued, will be successful. There is no assurance that approximately 26 million

shares of LXRP common stock has been shorted since 2009, and no knowledge that

any shorting that has occurred is illegal or contrary to various regulations.

Lexaria has not independently verified the data provided by any third party

including www.buyins.net There is no assurance that any of Lexaria's

postulated uses, benefits, or advantages for the patent-pending technology will

in fact be realized in any manner or in any part.

The CSE has not reviewed and does not accept responsibility

for the adequacy or accuracy of this release.